Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (NYSE: BDX) was honored by the Healthcare Industry Resilience Collaborative on April 16, 2026 as the only supplier to win HIRC's inaugural Member Choice Awards in Transparency, Resiliency and Partnership. The awards reflect member-selected recognition for real-world supply chain performance, data sharing, and collaborative execution.
BD noted prior HIRC recognitions, including the Transparency Badge four years running and the Resiliency Badge in 2025, and highlighted its role on HIRC councils shaping standards and best practices.
BD (NYSE: BDX) will report financial results for its second quarter of fiscal 2026 on Thursday, May 7, 2026.
Management will host an audio webcast at 8:00 a.m. ET to discuss results for the quarter ended March 31, 2026, and to provide an update on operations and strategy. Materials and replay will be available at www.bd.com/investors.
BD (NYSE: BDX) announced that Richard (Rick) Byrd will retire after nearly 25 years with the company, remaining in his role through June 2026. Byrd is executive vice president and president of the Interventional Segment since September 2022 and previously led Medication Delivery Solutions and Preanalytical Systems.
BD said Byrd helped expand leadership in Vascular Access Management, advance the One‑Stick Hospital Stay vision and lead manufacturing scale‑up during the COVID‑19 pandemic. BD intends to name a successor prior to his retirement.
BD (NYSE: BDX) announced new clinical findings (April 9, 2026) showing the PureWick® Urine Collection System helped women with nighttime urinary incontinence report better sleep, greater comfort, and ease of use.
In a four-week randomized trial of 165 women across 13 U.S. sites, ~70% said they would continue using PureWick®; study noted low skin irritation and effective urine capture.
BD (NYSE:BDX) announced CE Marking for the Liverty™ TIPS Stent Graft, an adjustable‑diameter device (6–10 mm) designed to treat portal hypertension complications across the EU. Safety and effectiveness data from the pivotal ARCH clinical trial will be presented at the Society of Interventional Radiology Annual Meeting on April 12, 2026.
The device offers a broad range of covered TIPS stent lengths, a flexible nitinol frame, dual‑layer ePTFE encapsulation, and a triaxial delivery system. In the U.S. the device remains investigational.
BD (NYSE: BDX) on April 7, 2026 launched the HemoSphere Stream™ Module, a compact device that streams continuous, noninvasive beat-to-beat arterial waveform data to compatible multiparameter bedside monitors.
Used with the VitaWave™ Plus Finger Cuff, it forms the VitaWave™ Plus System, validated against arterial line measurements and designed to broaden continuous blood pressure monitoring across care settings.
BD (NYSE: BDX) announced the European launch of the BD Pyxis Pro Dispensing Solution and the BD Incada Connected Care Platform on April 1, 2026.
The systems combine advanced automation, AI-driven analytics and connected data to improve medication inventory control, security (RFID, barcode, illuminated bins), refrigerated-to-ambient storage capacity and clinician efficiency. The Pyxis Pro will roll out across Europe with support for 15 languages, and BD plans to extend BD Incada Analytics to European hospitals next year using the AWS European Sovereign Cloud.
BD (NYSE: BDX) received FDA 510(k) clearance on March 2, 2026 for Surgiphor™ 1000mL, the first 1000 mL antimicrobial irrigation system designed for powered lavage. Surgiphor™ 1000mL is terminally sterile, ready-to-use, and built to integrate with common powered lavage devices to standardize wound irrigation and improve OR efficiency.
Key features include a powered-device adapter, Y-connector for quick switching, optimized flow with integrated venting, and a collapsible bottle for handling and evacuation.
Becton, Dickinson and Company (NYSE: BDX) announced pricing and accepted amounts for previously announced tender offers to purchase up to $2,000,000,000 aggregate principal amount (the Aggregate Offer Cap) of multiple series of its senior notes.
The company set Total Consideration per $1,000 for each series, will settle early on February 27, 2026 for early tenders, and allocated accepted principal by series (notable acceptances include $656,047,000 of 4.669% notes, $472,349,000 of 4.685% notes, $444,588,000 of 5.081% notes and $262,727,000 of 3.794% notes).
Becton, Dickinson and Company (NYSE: BDX) announced early tender results and an upsizing of its tender offers. The company increased the Aggregate Offer Cap from $1,600,000,000 to $2,000,000,000 and raised the Offer SubCap for its 4.685% Senior Notes due 2044. Withdrawal rights expired Feb 24, 2026; the company elected an Early Settlement Date of Feb 27, 2026. Securities accepted for purchase will be retired and cancelled. Total consideration will be determined by fixed spreads plus Treasury yields at 10:00 a.m. ET on Feb 25, 2026.